Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- AUPH +3.5% (guidance), SVV +1.2% (guidance), SCPH +0.6%
News:
- FUSN +11.8% (clinical program and manufacturing updates)
- LAB +7.8% (Standard BioTools Stockholders Approve Merger with SomaLogic)
- AXGN +7.4% (CEO to retire; also guides to Q4 upside revs)
- DCPH +7.3% (announced that Nature Medicine has published results from a circulating tumor DNA analysis of the INTRIGUE Phase 3 study of QINLOCK in GIST patients with mutations in KIT exon 11 and 17/18 only previously treated with imatinib)
- NVCR +5% (names new CMO)
- CVAC +3.1% (announced positive interim data from the ongoing Phase 2 study assessing monovalent and bivalent modified vaccine candidates against COVID-19) IMCR +2% (sets out its strategic priorities for 2024 and announced the addition of two new pre-clinical candidates for autoimmune diseases to its pipeline)
- PRQR +2% (collaboration with the Rett Syndrome Research Trust)
- RMBL +1.9% (entered into a Purchase Agreement on Dec 29)
- ASR +1.7% (reports Dec traffic)
- KOPN +1.4% (forms strategic agreement with MICLEDI Microdisplays to make microLED displays)
- PSN +1.2% (launches Freight Intelligent Transportation System to improve port ops)
- COST +0.9% (December comps)